How does Scholar Rock’s Isembyld fit with SMN2 drugs in SMA?

Scholar Rock’s newly approved Isembyld is positioned as an add-on to SMN2-targeting drugs, not a replacement. In a late-stage trial, the combination improved young SMA patients’ motor skills after a year, and Isembyld was described as the first drug aimed at SMA-related muscle loss.